CHMP adopts positive opinion for the marketing authorization of Bayer's (BAYN GY) Finerenone for patients with heart failure with left ventricular ejection fraction ≥40%

30 Jan 2026 - 12:24- Equities- Source: Market Source

Bayer AGPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals (Group)PharmaceuticalsBAYN.GYEuropeEquitiesGermanyBAYNDAX 40 IndexEURO STOXX 50US SessionEU SessionUS SessionEU Session

Subscribe Now to Newsquawk

Click here for a 1 week free trial

Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include: